HDAC6-IN-84
HDAC6-IN-84 is a potent and selective HDAC6 inhibitor with an IC50 of 25.56 nM and shows 478-fold selectivity over HDAC1. HDAC6-IN-84 increases α-tubulin acetylation and upregulates BDNF (exons I and IV) and other neurogenesis-related genes. HDAC6-IN-84 can be used for the study of Alzheimer’s disease (AD) and other neurodegenerative diseases.
For research use only. We do not sell to patients.
- CAS No.: 3053402-10-8
- Formula: C17H16N2O3S
- Molecular Weight:328.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
HDAC6 25.56 nM (IC50) |
HDAC6-IN-84 (5h) inhibits HDAC6 with an IC50 of 25.56 nM and shows 478-fold selectivity over HDAC1[1].
HDAC6-IN-84 eliminates activity against HDAC2 and class IIa HDACs and further reduces activity against class I HDACs (HDAC1 and HDAC3)[1].
HDAC6-IN-84 (0.3-3 μM; 24 h) promotes α-tubulin acetylation in SH-SY5Y and HeLa cells, while negligibly affecting histone H3 acetylation[1].
HDAC6-IN-84 (0.1-10 μM; 24 h) shows low cytotoxicity in SH-SY5Y cells and HeLa cells.
HDAC6-IN-84 (1 μM) promotes neuronal gene activation and may enhance synaptic plasticity and development in human iPSC-derived NPCs[1].
HDAC6-IN-84 (1 μM; 24-48 h) upregulates BDNF exons I, II, and IV in human iPSC-derived neural progenitor cells (NPCs)[1].
HDAC6-IN-84 shows low inhibitory activities against CYP2C9, CYP2C19, CYP2D6, and CYP3A4 and exhibits low binding affinity to the hERG membrane channel, with an IC50 of 159.1 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SH-SY5Y cells, HeLa cells
-
Concentration:0.3 μM, 1 μM, 3 μM
-
Incubation Time:24 h
-
Result:Promoted α-tubulin acetylation in a concentration-dependent manner while negligibly affecting histone H3 acetylation.
Selectively inhibited HDAC6 in the tested cells.
-
Cell Line:SH-SY5Y cells, HeLa cells
-
Concentration:0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM
-
Incubation Time:24 h
-
Result:Showed low cytotoxicity in SH-SY5Y cells and HeLa cells.
-
Cell Line:human iPSC-derived NPCs
-
Concentration:1 μM
-
Incubation Time:24 h
-
Result:Upregulated BDNF exons I, II, and IV.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male 4-week-old ICR mice were treated with Scopolamine (HY-N0296) ( administered 30 min after compound treatment)[1].
-
Dosage:0.015 mg/kg, 0.05 mg/kg, 0.15 mg/kg
-
Administration:Intraperitoneal injection (i.p.); single administration
-
Result:For the 24 h-training session, no group differences in step-through latency were observed.
Markedly recovered the scopolamine-induced impairment and restored step-through latency.
Chemical Information
-
CAS No. 3053402-10-8
-
Molecular Weight 328.39
-
Formula C17H16N2O3S
-
SMILES
O=C(NO)CCC1=CSC(C2=CC=C3C=C(OC)C=CC3=C2)=N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HDAC6-IN-84 Related Classifications
HY-184424 Related Classifications
Powered by Bioz